ArriVent BioPharma (AVBP) Cash from Financing Activities (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Cash from Financing Activities data on file, last reported at $54.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 711.85% year-over-year to $54.9 million; the trailing twelve-month figure through Mar 2026 stood at $251.2 million (up 3158.65% YoY), and the FY2025 full-year result was $203.1 million, up 8.83% from the prior year.
• Cash from Financing Activities climbed to $54.9 million in Q1 2026, from $34.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $185.6 million in Q1 2024 to a low of -$1.1 million in Q4 2023.
• A 4-year average of $37.5 million and a median of $6.8 million in 2025 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 63036.36% in 2025, while the deepest fall reached 96.36% in 2025.
• Tracing AVBP's Cash from Financing Activities over 4 years: stood at -$1.1 million in 2023, then jumped by 105.2% to $55000.0 in 2024, then soared by 63036.36% to $34.7 million in 2025, then surged by 58.02% to $54.9 million in 2026.
• Business Quant data shows AVBP's Cash from Financing Activities at $54.9 million in Q1 2026, $34.7 million in Q4 2025, and $86.5 million in Q3 2025.